Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss
|ClinicalTrials.gov Identifier: NCT01735331|
Recruitment Status : Completed
First Posted : November 28, 2012
Last Update Posted : August 7, 2015
|Condition or disease|
|Recurrent Pregnancy Loss Without Current Pregnancy|
This study is a prospective,observational,single-center study.Ethical approval was obtained from the Institutional Review Board.This study will be completed 30 patients with Habitual Abortus.
Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1) antibody kits. All assays will be performed according to the manufacturer's instructions.
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Observational Model:||Case Control|
|Official Title:||Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
Patients with Abnormal Uterine Bleeding
- The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss [ Time Frame: 3 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01735331
|Bagcilar Training and Research Hospital|
|Principal Investigator:||TANER A. USTA, M.D.||Bagcilar Training and Research Hospital,Istanbul,Turkey.|